Follistatin-344: A Precursor Isoform Studied in Muscle and Metabolic Research

Research summary. Follistatin-344 (FST-344) is a 344-amino-acid glycoprotein precursor produced by the FST gene. In native biology, it is processed proteolytically to yield the mature circulating forms, principally FST-315 and FST-288. The 344-residue form retains a 29-residue signal peptide that is cleaved during secretion. In research and gene-therapy contexts, FST-344 is frequently the form encoded in transgene constructs because it represents the natural pre-secretory protein and supports correct downstream trimming and folding.

Molecular profile

• Length: 344 amino acids (precursor form)
• Molecular weight: ~37.8 kDa
• Class: Secreted glycoprotein, follistatin family
• Synonyms: FST-344, full-length follistatin precursor
• Native processing: Cleaved to mature FST-315 and FST-288 isoforms

In gene-therapy research, the FST-344 cDNA is commonly the construct of choice because it provides the natural precursor sequence for cellular processing into mature follistatin. This is why much of the muscle hypertrophy gene-therapy literature refers specifically to "FST-344 expression vectors" rather than to a directly administered protein.

Mechanism of action

Once processed and secreted, FST-344-derived mature follistatin acts through the same mechanism as exogenously administered FST-315 or FST-288: it functions as a high-affinity decoy receptor for TGF-β superfamily ligands, sequestering activin A, myostatin (GDF-8), and GDF-11 to prevent engagement of the activin receptor (ActRIIA/B). The downstream effect in skeletal muscle is removal of myostatin- and activin-mediated brakes on muscle hypertrophy.

A point worth noting: studies that report "follistatin-induced muscle growth" using FST-344 are typically reporting the activity of mature FST-315 and FST-288 generated from the precursor, not the precursor itself.

Preclinical research highlights

Skeletal muscle hypertrophy without exercise. Murine studies of FST-344 gene-therapy (typically AAV-mediated intramuscular delivery) have reported sustained increases in muscle mass on the order of ~10% at eight weeks following a single injection, without exercise conditioning. The reported hypertrophy persists for the duration of transgene expression, which can extend over multi-year follow-up in the AAV vector context [1].

Duchenne muscular dystrophy models. AAV-FST-344 administration in mdx and other DMD-relevant rodent models has reported improvements in functional strength metrics, reduced fibrosis, attenuated inflammatory cell infiltration, and dose-dependent increases in fibre cross-sectional area. These findings have supported continued translational interest in follistatin gene therapy as a candidate for muscular dystrophy research.

Metabolic and beta-cell biology. Sustained follistatin expression in diabetic rodent models has been associated with expansion of pancreatic beta-cell mass, normalisation of fasting glucose, and improved survival metrics. Follistatin's role in cross-talk between TGF-β superfamily signalling and insulin/IGF-1 pathways has supported continued investigation of its endocrine effects beyond muscle.

Oncology context. Tumour biology studies with follistatin have produced complex, context-dependent findings. In some breast and HER2+ cancer models, follistatin overexpression has been reported to enlarge primary tumour volume while reducing metastatic spread, attributed to inhibition of activin-driven cellular migration. In hepatocellular contexts, activin blockade by follistatin appears important for normal hepatocyte proliferation, complicating any simple narrative about follistatin as universally pro- or anti-tumourigenic.

Hair growth research. Combination dermal studies pairing follistatin with Wnt agonists in animal models have reported increases in hair density and shaft thickness following a single intradermal injection, attributed to modulation of TGF-β family signalling within the hair follicle niche.

Barrett's esophagus and BMP signalling. Investigations have explored follistatin as a candidate antagonist of excessive BMP signalling in models of Barrett's esophagus, a precursor lesion to esophageal adenocarcinoma.

Why FST-344 specifically

In molecular biology and gene-therapy contexts, FST-344 is preferred over FST-315 or FST-288 cDNAs because it represents the natural precursor with intact signal peptide and processing sites. Cells transduced with an FST-344 vector secrete the precursor, which is then processed extracellularly into the mature FST-315 and FST-288 forms in the appropriate ratio. This is functionally important: cells given an FST-288 cDNA construct, for example, may produce a protein lacking the natural balance of circulating versus tissue-bound forms.

For protein-based research not involving gene therapy, mature FST-315 or FST-288 are typically preferred over the FST-344 precursor.

Current research status

Follistatin-344 remains an investigational research protein and gene-therapy target. It has not received broad regulatory approval. Active areas of research include:

• AAV-mediated gene therapy for muscular dystrophy and other muscle-wasting conditions
• Endocrine and metabolic studies of follistatin's role in insulin sensitivity and beta-cell biology
• Hair-growth and dermatologic research with follistatin combinations
• Mechanistic studies of follistatin processing and tissue-specific isoform balance

Key takeaways for researchers

• FST-344 is the 344-residue precursor form of follistatin, processed extracellularly to mature FST-315 and FST-288.
• In gene-therapy and molecular biology contexts, FST-344 cDNA is the preferred construct because it supports natural processing to mature isoforms.
• AAV-FST-344 muscle gene therapy in animal models produces sustained hypertrophy without exercise.
• Reported activity spans muscular dystrophy, beta-cell metabolism, oncology context-dependent effects, and dermatology research.
• Follistatin and its derivatives are on the WADA Prohibited List. None has received broad therapeutic approval.

References

1. Lee SJ. Regulation of muscle mass by myostatin. Annual Review of Cell and Developmental Biology. 2004;20:61–86.

---

This article is provided for educational and research purposes only. Follistatin-344 is a research protein and gene-therapy target. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. Follistatin-related interventions are listed by the World Anti-Doping Agency as prohibited substances. All work involving this protein should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.